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Abstract
In some cases pregnancies are associated with severe cases of cardiovascular diseases (CVDs). The early
detection and proper treatment of CVDs during maternity is detrimental to the health outcome and wellbeing of both
mother and child. Unfortunately, both the detection rate and assessment of CVDs during pregnancies are
unsatisfactory.
Currently, the messenger RNA (mRNA) regulators called microRNAs (miRNAs) are being extensively profiled for
use as clinical CVDs biomarkers due to their specific tissue and disease expression signature profiles. The
identification and development of reliable biomarkers for early clinical assessment of CVDs during pregnancy could
allow the detection of sub-clinical cardiac injury risk in vulnerable pregnant patients before irreversible damage
occurs. CVDs specific miRNA biomarkers could provide the clinicians with a valuable tool to allow prognosis of
patients at risk of cardiovascular injury and the introduction of therapy and intervention in order to increase health
outcome and survival rate of both the mother and child.
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Cardiac diseases during pregnancy
Cardiac diseases account for 2-4 % of maternal death associated
with pregnancy and the maternal mortality rate due to cardiac diseases
has been reported to be 2.31 per 100,000 maternities in United
Kingdom (UK) in 2006-2008 [5]. The most frequent form of cardiac
disease in pregnant women is congenital heart condition, which is
characterised by tiredness and fatigue, shortness of breath, dizziness,
rapid heartbeat and/or chest pain [6].
Classification Symptoms and limitations
Class I   
No symptoms from ordinary activities
No limitation of activities
Class II   
Comfortable with rest or mild exertion
Fatigue, palpitation, dyspnea and/or anginal pain with more than ordinary physical activity
Slight/mild limitation of activity
Class III   
Comfortable with rest
Fatigue, palpitation, dyspnea and/or anginal pain with less than ordinary physical activity
Marked limitation of activity
Class IV   
Discomfort is increased if any physical activity is undertaken
Even at rest symptoms of cardiac insufficiency or of anginal syndrome may be present
Any physical activity brings on discomfort and symptoms occur at rest
Modified from American Heart Association website www.heart.org (2015)
Table 1: New York Heart Association: Functional Classification of Heart Diseases.
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As the blood volume is increased during pregnancy it is expected to
have some of this symptoms, making it difficult to distinguish when
this due to an impaired heart. A physical examination will determine if
any cardiac abnormalities are present. In case a cardiac disease is
detected the damage will be localised and specified (eg. valve, cardiac
muscle, endocardium or arrhythmia) and whether it is congenital or
acquired will be determined. The severity of the injury will be assessed
using the New York Heart Association (NYHA) classification of heart
disease (American Heart Association guidelines: www.heart.org)
(Table 1). Fortunately, the majority of heart diseases (>90%) observed
during pregnancy are class I and II and are therefore not linked with
any substantial symptoms or risks involved for nor mother or child.
However, some pregnancy cases involve class III and IV heart diseases
and are associated with more complications and are usually diagnosed
prior to pregnancy (Table 2). Peripartum cardiomyopathy (PPCM) is a
very severe life-threatening idiopathic form of heart failure due to left
ventricular systolic dysfunction [7]. PPCM is observed in the last
month of pregnancy or within 5 months after delivery and is quite rare
as PPCM affects approximately 1 in 2,000 pregnancies in UK [8] and
accounts for about 1 in 6 deaths linked to cardiac disease during
pregnancies [9]. The incidence of PPCM is much higher in developing
nations, such as Haiti (1 in 300) and South Africa (1 in 1,000) [10-12].
A report by Cantwell et al. 2011, showed that a total of 53 pregnant
women died due to cardiac maternal deaths during 2006-2008 in UK,
and half of these women were never assessed by electrocardiograms or
cardiac injury biomarkers [5], highlighting that there were critical
lessons to be learnt from their health management.
Risk of maternal mortality Mortality rate Cardiac lesion types
Low (<1%)   
Most Class I or II lesions of NYHA
Patent ductus arteriosus
Pulmonic/ tricuspid lesions Septal defects   
Moderate (5%-15%)   
Most Class III or IV NYHA lesions, especially mitral stenosis
Tetralogy of Fallot Aortic stenosis
History of Myocardial Infarction
Marfan syndrome with normal aorta   
High (25%-50%)   
Eisenmenger's syndrome
Marfan syndrome with abnormal aortic root
Peripartum cardiomyopathy
Pulmonary hypertension   
Modified from Handbook of Critical Care Obstetrics (by S.L. Clark, J.P. Phelan, G. Hankins & D.Cotton), 1st Ed, Wiley-Blackwell (1994).
Table 2: Risk of maternal mortality and cardiac lesion types observed.
Potential biomarkers for cardiac injury assessment: miRNAs
The short (~22 nucleotides), single-stranded, non-coding RNA
molecules called miRNAs play an important role in post-
transcriptional gene regulation, as they induce mRNA translation
repression or degradation [13]. So far >1,000 miRNAs have been
detected in the human genome (www.miRBase.org). One miRNA can
target and regulate several mRNAs, and furthermore, one mRNA can
be targeted and regulated by a diverse set of miRNAs [14]. The key
functions of miRNAs include differentiation, proliferation, apoptosis,
metabolic homeostasis, tumorigenesis and DNA methylation [15-17].
Determining the miRNA profile can provide vital information on the
physiological and pathological state [17].
Cardiac diseases and miRNA expression
As pointed out by Yang et al. 2008, miRNAs have different
expression signature under different pathological conditions [18]. A
comparison of various studies investigating miRNA profiles in
ischemic myocardium and hypertrophic hearts affirmed that the
miRNA expression went in the opposite directions between these two
pathological conditions. During cardiac hypertrophy miR-208,
miR-214, miR-320 and miR-351 are upregulated, while the same
miRNAs are downregulated in myocardial infarction. During
myocardial infarction miR-1, miR-29a, miR-30 and miR-181b are
upregulated, while the opposite effect is observed during cardiac
hypertrophy. In addition, cardiac dysfunction has been associated with
an altered expression of miR-21, miR-27b, miR-29, miR-126 and
miR-195 [19-22], while an altered expression of miR-1, miR-133a,
miR-133b, miR-208a and miR-499-5p is observed during acute
myocardial infarction [23-26]. Arrhythmias have showed an altered
expression of miR-1, miR-133 and miR-208a [27-29], while fibrosis is
associated with alteration of miR-21 and miR-29 [18,22].
Cardiac diseases during pregnancy and miRNA profiling as a
screening tool
As a result of limited sensitivity and specificity and the high costs
and availability of current techniques for assessing cardiac injury (i.e.
imaging techniques such as Doppler echocardiography,
endomyocardial biopsies and serum protein biomarkers) there is an
urgent need for developing a new non-invasive and cost-effective
diagnostic tool for early detection of cardiac injury [30-32].
Investigating the miRNA expression profiles of pregnant women in the
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risk zone for cardiac diseases may be useful for diagnosis and
prediction of pregnancy-related cardiac diseases [33]. Some studies
have looked at the miRNA expression profiles linked with CVDs and
preeclampsia in placental tissue [34,35]; however, it is more beneficial
to sample the maternal circulation for early detection of cardiac injury,
by potentially implementing miRNAs as biomarkers in clinical
assessment routines. A study by Hromadnikova et al. 2013, showed
that upregulation of miR-516-5p, miR-517, miR-520a, miR-525, and
miR-526a is a characteristic phenomenon of established preeclampsia
[36]. Furthermore, the downstream-mediator of 16-kDa N-terminal
prolactin fragment miR-146a was elevated in the plasma and hearts of
PPCM patients, but not in patients with dilated cardiomyopathy
[37,38]. Studies have shown that placental miRNAs are released into
the maternal circulation [14] and these miRNAs may have an
important role in development of CVDs in the mother and should be
examined carefully.
Conclusion
Novel examination into miRNA expression profiles of pregnant
women prone to develop or with known profiles of cardiac diseases
will give a valuable screening tool to detect cardiac injury risk at an
early stage and ensuring that the clinicians can tackle the symptoms
before an irreversible stage is reached, thus improving the outcome for
both mother and child.
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